reports
Hudson Pacific Properties Inc: 1 director
A director at Hudson Pacific Properties Inc sold 127,918 shares at 5.720USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Rapid7 to Attend Upcoming Investor Conferences
Rapid7 to Attend Upcoming Investor Conferences BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RPD), a leader in extended risk and threat detection, today announced that the company will be attending the following conferences: The J.P. Morgan 52nd Annual Global Technology, Media and Communications Conference in Boston, MA. The presentation is scheduled for Tuesday May 21, 2024 at 3:45 p.m. Eastern Time.The 2nd Annual UBS Women in Tech Summit in San Francisco, CA on Tuesday, June 11th. The presentation from the J.P. Morgan 52nd Annual Global Technology, Media and Communications Confer...
Savara Announces New Employment Inducement Grant
AUSTIN, Texas--(BUSINESS WIRE)-- (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee. On May 14, 2024, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company. The inducement awards consist of options to purchase 15,000 shares of the Company’s common stock and restricted stock units (RSUs) covering 2,500 shares of the Company’s common stock. These equity awards were granted under the Savara Inc. 2021 I...
CORRECTION - Macerich Announces Initial Progress in its Path Forward S...
CORRECTION - Macerich Announces Initial Progress in its Path Forward Strategic Plan Macerich Purchases Remaining 40% Share of Arrowhead Towne Center (a Top 10 NOI Center for Macerich) and South Plains Mall from JV Partner, and Commits to the Sale of a Prominent Retail Asset SANTA MONICA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Macerich (NYSE: MAC), please note in the third paragraph, the amount the transaction is expected to generate has been corrected to $110 million of net proceeds. The corrected release follows: Macerich ...
UPDATE - Macerich Announces Initial Progress in its Path Forward Strat...
UPDATE - Macerich Announces Initial Progress in its Path Forward Strategic Plan Macerich Purchases Remaining 40% Share of Arrowhead Towne Center (a Top 10 NOI Center for Macerich) and South Plains Mall from JV Partner, and Commits to the Sale of a Prominent Retail Asset SANTA MONICA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Macerich (NYSE: ), one of the nation’s leading owners, operators and developers of major retail properties in top markets, today announced its purchase of the remaining 40% share of both Arrowhead Towne Center (Metro Phoenix) and South Plains Mall (Lubbock, Texas) fo...
Macerich Announces Initial Progress in its Path Forward Strategic Plan
Macerich Announces Initial Progress in its Path Forward Strategic Plan Macerich Purchases Remaining 40% Share of Arrowhead Towne Center (a Top 10 NOI Center for Macerich) and South Plains Mall from JV Partner, and Commits to the Sale of a Prominent Non-Mall Asset SANTA MONICA, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Macerich (NYSE: ), one of the nation’s leading owners, operators and developers of major retail properties in top markets, today announced its purchase of the remaining 40% share of both Arrowhead Towne Center (Metro Phoenix) and South Plains Mall (Lubbock, Texas) for $36.5...
- Valens Research
Clarus Announces Upcoming Investor Conference Schedule
Clarus Announces Upcoming Investor Conference Schedule SALT LAKE CITY, May 15, 2024 (GLOBE NEWSWIRE) -- Clarus Corporation (NASDAQ: CLAR) (“Clarus” and/or the “Company”), a global company focused on the outdoor enthusiast markets, announced today that Chief Financial Officer Mike Yates will be participating in the following investor conferences: 24th Annual B. Riley Institutional Investor Conference on Wednesday, May 22, 2024 in Beverly Hills, CA.Stifel Cross Sector Insight Conference on Tuesday, June 4, 2024 in Boston, MA. Company presentation timing is 3:35 – 4:05 PM ET.Jefferies Consu...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Ass...
IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, announced today a presentation at the European Hematology Association 2024 Congress, to be held June 13-16 in Madrid, Spain. “We’re excited to share the latest updated interim results from our Phase 1 trial evaluating our gamma-delta T cell therapy INB-100 after haploidentical stem cell transplantation for patients with leukemia at the upcoming EHA c...
Highwoods Publishes 2023 Corporate Resiliency Report
Highwoods Publishes 2023 Corporate Resiliency Report RALEIGH, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Highwoods Properties, Inc. (NYSE: HIW) has published its 2023 Corporate Resiliency Report, which highlights the Company’s Environmental, Social and Governance initiatives. A copy of the report can be accessed by clicking on the link below and on the Company’s website at /sustainability. In 2023, our continued efforts to advance our ESG and resiliency strategy have earned us: GRESB: A Green Star rating for the fourth consecutive year and continued year-over-year performance improv...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy...
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company advancing innovative gamma-delta T cell therapies, presented in an oral session details about its robust and reproducible proprietary clinical-scale gamma-delta T cell manufacturing platform across different donor populations, at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting. In an oral presentation titled: “Healthy Donor vs. Patient Manufac...
- Jonathan Moreland
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
SAIA SAIA INC.
RYI RYERSON HOLDING CORPORATION
RM REGIONAL MANAGEMENT CORP
RHP RYMAN HOSPITALITY PROPERTIES INC.
PENN PENN NATIONAL GAMING INC.
LTRX LANTRONIX INC.
KMPR KEMPER CORPORATION
HUBB HUBBELL INCORPORATED CLASS B
HOO HERBALIFE NUTRITION LTD.
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CNMD CONMED CORPORATION
AXS AXIS CAPITAL HOLDINGS LIMITED
AMH AMERICAN HOMES 4 RENT CLASS A
AIN ALBANY INTERNATIONAL CORP. CLASS A
HWBK HAWTHORN BANCSHARES
EFR ENERGY FUELS
SABR SABRE CORP.
ALPN ALPINE SELECT AG
HTLD HEARTLAND EXPRESS INC.
MAC MACERICH COMPANY
HI HILLENBRAND INC.
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
CRVS CORVUS PHARMACEUTICALS
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
EAF GRAFTECH INTERNATIONAL
FRAF FRANKLIN FINANCIAL SERVICES CO.
BBDC BARINGS BDC INC.
GH GUARDANT HEALTH
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
CZR CAESARS ENTERTAINMENT INC
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
TBBK INC.
MEGI THE BANCORP
NPCT INC.
RXO_w MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w RXO INC
NBBK BEYON 3D LTD
ASGI VESTIS CORPORATION
EYPT NB BANCORP INC.
DBD ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
EYEPOINT PHARMACEUTICALS
INC.
DIEBOLD NIXDORF INCORPORATED
- Jonathan Moreland
KMPR KEMPER CORPORATION
HOO HERBALIFE NUTRITION LTD.
CNMD CONMED CORPORATION
SABR SABRE CORP.
ALPN ALPINE SELECT AG
MAC MACERICH COMPANY
WDFC WD-40 COMPANY
PK PARK HOTELS & RESORTS INC.
EAF GRAFTECH INTERNATIONAL
BBDC BARINGS BDC INC.
MCFT MASTERCRAFT BOAT HOLDINGS
HQL TEKLA LIFE SCIENCES INVESTORS
PSTV PLUS THERAPEUTICS INC
CTOS CUSTOM TRUCK ONE SOURCE
NPCT INC.
BYON NUVEEN CORE PLUS IMPACT FD
VSTS_w BEYON 3D LTD
ASGI VESTIS CORPORATION
ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 20,250 shares of its common stock to eleven newly-hired employees, with a grant date of May 6, 2024 (the "Grant Date"). The restricted stock units were granted pursua...
- Jonathan Moreland
TELA Bio Reports First Quarter 2024 Financial Results
TELA Bio Reports First Quarter 2024 Financial Results MALVERN, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Reported revenue of $16.6 million in the first quarter, representing growth of 39% over the prior year period of 2023;Delivered the 13th consecutive quarter of at least 35% year-over-year growth;Increased demand for OviTex® and OviTex PRS Reinforced Tis...
Savara Reports First Quarter 2024 Financial Results and Provides Busin...
LANGHORNE, Pa.--(BUSINESS WIRE)-- (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and provided a business update. “The IMPALA-2 trial remains on-track and we look forward to reporting top line results by the end of the second quarter,” said Matt Pauls, Chair and CEO, Savara. “Following that, and assuming positive data, we expect to file a BLA in the first half of 2025. Importantly, with $143 million in cash and investments, we believe we are capitalized into ...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corpora...
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Presented new preclinical data demonstrating proof-of-concept for non-signaling Chimeric Antigen Receptor (nsCAR) platform to effectively target cancer cells while preserving healthy tissue - Demonstrated potential of nsCAR platform to treat previously “undruggable” solid and liquid tumor targets - Announced peer-reviewed publication in ‘Frontiers in Immunology’ on IN8bio’s DeltEx Drug Resistant Immunotherapy (DRI) approach to newly diagnosed glioblastoma multiforme (GBM) - Dosed first patient in auto...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.